McKesson Europe AG provides logistics and services to the pharmaceutical and healthcare sectors worldwide.
Mediocre balance sheet not a dividend payer.
Share Price & News
How has McKesson Europe's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CLS1 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CLS1 matched the German Healthcare industry which returned -1.7% over the past year.
Return vs Market: CLS1 underperformed the German Market which returned -0.7% over the past year.
Price Volatility Vs. Market
How volatile is McKesson Europe's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall StAre Investors Concerned With What's Going On At McKesson Europe (HMSE:CLS1)?
1 month ago | Simply Wall StShould You Or Shouldn't You: A Dividend Analysis on McKesson Europe AG (HMSE:CLS1)
4 months ago | Simply Wall StIs McKesson Europe AG (HMSE:CLS1) An Attractive Dividend Stock?
Is McKesson Europe undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CLS1 (€26.1) is trading above our estimate of fair value (€16.78)
Significantly Below Fair Value: CLS1 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CLS1 is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.
PE vs Market: CLS1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CLS1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CLS1 is overvalued based on its PB Ratio (2.7x) compared to the DE Healthcare industry average (1.4x).
How is McKesson Europe forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as McKesson Europe has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of CLS1’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore growth companies in the Healthcare industry.
How has McKesson Europe performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CLS1 is currently unprofitable.
Growing Profit Margin: CLS1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CLS1's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CLS1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLS1 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (9.7%).
Return on Equity
High ROE: CLS1 has a negative Return on Equity (-2.62%), as it is currently unprofitable.
How is McKesson Europe's financial position?
Financial Position Analysis
Short Term Liabilities: CLS1's short term assets (€5.3B) exceed its short term liabilities (€3.7B).
Long Term Liabilities: CLS1's short term assets (€5.3B) exceed its long term liabilities (€1.4B).
Debt to Equity History and Analysis
Debt Level: CLS1's debt to equity ratio (49.5%) is considered high.
Reducing Debt: CLS1's debt to equity ratio has increased from 45.3% to 49.5% over the past 5 years.
Debt Coverage: CLS1's debt is well covered by operating cash flow (35.1%).
Interest Coverage: CLS1 is unprofitable, therefore interest payments are not well covered by earnings.
What is McKesson Europe current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CLS1's dividend (3.18%) is higher than the bottom 25% of dividend payers in the German market (1.28%).
High Dividend: CLS1's dividend (3.18%) is low compared to the top 25% of dividend payers in the German market (3.82%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, CLS1 has been paying a dividend for less than 10 years.
Growing Dividend: CLS1 has only been paying a dividend for 3 years, and since then payments have not increased.
Current Payout to Shareholders
Dividend Coverage: CLS1 is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Kevin Kettler has been Chairman of the Management Board at McKesson Europe AG since November 1, 2018 and its Labour Relations Director since November 2018.
|CFO & Member of the Management Board||6yrs||€219.00k||no data|
|Labour Relations Director||5.83yrs||€277.00k||no data|
|Chairman of the Management Board & Labour Relations Director||1.67yrs||no data||no data|
|Head of Corporate Investor Relations||no data||no data||no data|
Experienced Management: CLS1's management team is seasoned and experienced (5.8 years average tenure).
|Deputy Chairman of the Supervisory Board||no data||€20.30k||no data|
|Deputy Chairman of the Supervisory Board||no data||€26.40k||no data|
|Employee Representative Member of the Supervisory Board||11.08yrs||€16.80k||no data|
|Member of the Supervisory Board||4yrs||no data||no data|
|Chairman of Supervisory Board||1.92yrs||no data||no data|
|Employee Representative Member of the Supervisory Board||12.25yrs||€16.80k||no data|
|Member of the Supervisory Board||7.17yrs||€16.80k||no data|
|Employee representative Member of the Supervisory Board||2.92yrs||no data||no data|
|Employee representative Member of the Supervisory Board||2.42yrs||no data||no data|
|Shareholder Representative of the Supervisory Board||0.25yr||no data||no data|
Experienced Board: CLS1's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
McKesson Europe AG's company bio, employee growth, exchange listings and data sources
- Name: McKesson Europe AG
- Ticker: CLS1
- Exchange: HMSE
- Founded: 1835
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: €5.304b
- Shares outstanding: 203.22m
- Website: https://www.mckesson.eu/mck-en
Number of Employees
- McKesson Europe AG
- Stockholmer Platz 1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CAKF.Y||OTCPK (Pink Sheets LLC)||UNSPONSORED ADR||US||USD||No data|
|CAKF.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Jan 1992|
|0OPB||LSE (London Stock Exchange)||Yes||Registered Shares||GB||EUR||Jan 1992|
|CLS1||HMSE (Hamburg Stock Exchange)||Yes||Registered Shares||DE||EUR||Jan 1992|
|CAKF.Y||OTCPK (Pink Sheets LLC)||UNSPONSORED ADR||US||USD||Oct 2008|
McKesson Europe AG provides logistics and services to the pharmaceutical and healthcare sectors worldwide. The company operates through two divisions, Consumer Solutions and Pharmacy Solutions. The Consumer Solutions division operates approximately 2,000 own and 300 managed retail pharmacies and approximately 7,000 participants in its brand partnership schemes. The Pharmacy Solutions division engages in the wholesale of pharmaceutical products. It also provides supplementary services for pharmacists, such as the organization and management of pharmacy cooperation programs in the United Kingdom, Germany, France, Portugal, and Belgium. This division serves its customers through 118 wholesale branches that supplies approximately 100,000 pharmaceutical products to approximately 50,000 pharmacies and hospitals. The company was formerly known as Celesio AG and changed its name to McKesson Europe AG in September 2017. The company was founded in 1835 and is headquartered in Stuttgart, Germany. McKesson Europe AG operates as a subsidiary of McKesson Corporation.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/01 19:33|
|End of Day Share Price||2020/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.